423 related articles for article (PubMed ID: 35159370)
1. Mechanisms of Cisplatin Resistance in HPV Negative Head and Neck Squamous Cell Carcinomas.
Griso AB; Acero-Riaguas L; Castelo B; Cebrián-Carretero JL; Sastre-Perona A
Cells; 2022 Feb; 11(3):. PubMed ID: 35159370
[TBL] [Abstract][Full Text] [Related]
2. New advances into cisplatin resistance in head and neck squamous carcinoma: Mechanisms and therapeutic aspects.
Hu H; Li B; Wang J; Tan Y; Xu M; Xu W; Lu H
Biomed Pharmacother; 2023 Jul; 163():114778. PubMed ID: 37137185
[TBL] [Abstract][Full Text] [Related]
3. Role of p38 MAPK in disease relapse and therapeutic resistance by maintenance of cancer stem cells in head and neck squamous cell carcinoma.
Roy S; Roy S; Kar M; Padhi S; Saha A; Anuja K; Banerjee B
J Oral Pathol Med; 2018 May; 47(5):492-501. PubMed ID: 29575240
[TBL] [Abstract][Full Text] [Related]
4. Epigenetic modifications control loss of adhesion and aggressiveness of cancer stem cells derived from head and neck squamous cell carcinoma with intrinsic resistance to cisplatin.
Milan TM; Eskenazi APE; Bighetti-Trevisan RL; de Almeida LO
Arch Oral Biol; 2022 Sep; 141():105468. PubMed ID: 35679799
[TBL] [Abstract][Full Text] [Related]
5. Cisplatin induces Bmi-1 and enhances the stem cell fraction in head and neck cancer.
Nör C; Zhang Z; Warner KA; Bernardi L; Visioli F; Helman JI; Roesler R; Nör JE
Neoplasia; 2014 Feb; 16(2):137-46. PubMed ID: 24709421
[TBL] [Abstract][Full Text] [Related]
6. Pharmacological inhibition of MYC to mitigate chemoresistance in preclinical models of squamous cell carcinoma.
Liu S; Qin Z; Mao Y; Wang N; Zhang W; Wang Y; Chen Y; Jia L; Peng X
Theranostics; 2024; 14(2):622-639. PubMed ID: 38169606
[No Abstract] [Full Text] [Related]
7. p38 Mitogen-activated protein kinase modulates cisplatin resistance in Head and Neck Squamous Cell Carcinoma cells.
Roy S; Roy S; Anuja K; Thakur S; Akhter Y; Padhi S; Banerjee B
Arch Oral Biol; 2021 Feb; 122():104981. PubMed ID: 33302041
[TBL] [Abstract][Full Text] [Related]
8. Inhibition of carbonic anhydrases IX/XII by SLC-0111 boosts cisplatin effects in hampering head and neck squamous carcinoma cell growth and invasion.
Sarnella A; Ferrara Y; Auletta L; Albanese S; Cerchia L; Alterio V; De Simone G; Supuran CT; Zannetti A
J Exp Clin Cancer Res; 2022 Apr; 41(1):122. PubMed ID: 35365193
[TBL] [Abstract][Full Text] [Related]
9. Targeting of FSP1 regulates iron homeostasis in drug-tolerant persister head and neck cancer cells via lipid-metabolism-driven ferroptosis.
Wu YC; Huang CS; Hsieh MS; Huang CM; Setiawan SA; Yeh CT; Kuo KT; Liu SC
Aging (Albany NY); 2024 Jan; 16(1):627-647. PubMed ID: 38206305
[TBL] [Abstract][Full Text] [Related]
10. ATR inhibition sensitizes HPV
Leonard BC; Lee ED; Bhola NE; Li H; Sogaard KK; Bakkenist CJ; Grandis JR; Johnson DE
Oral Oncol; 2019 Aug; 95():35-42. PubMed ID: 31345392
[TBL] [Abstract][Full Text] [Related]
11. Cancer stem cell mediated acquired chemoresistance in head and neck cancer can be abrogated by aldehyde dehydrogenase 1 A1 inhibition.
Kulsum S; Sudheendra HV; Pandian R; Ravindra DR; Siddappa G; R N; Chevour P; Ramachandran B; Sagar M; Jayaprakash A; Mehta A; Kekatpure V; Hedne N; Kuriakose MA; Suresh A
Mol Carcinog; 2017 Feb; 56(2):694-711. PubMed ID: 27380877
[TBL] [Abstract][Full Text] [Related]
12. Reactive oxygen species in cancer stem cells of head and neck squamous cancer.
Qian X; Nie X; Yao W; Klinghammer K; Sudhoff H; Kaufmann AM; Albers AE
Semin Cancer Biol; 2018 Dec; 53():248-257. PubMed ID: 29935313
[TBL] [Abstract][Full Text] [Related]
13. p90RSK pathway inhibition synergizes with cisplatin in TMEM16A overexpressing head and neck cancer.
Yassin-Kassab A; Chatterjee S; Khan N; Wang N; Sandulache VC; Huang EH; Burns TF; Duvvuri U
BMC Cancer; 2024 Feb; 24(1):233. PubMed ID: 38373988
[TBL] [Abstract][Full Text] [Related]
14. Slug is a novel molecular target for head and neck squamous cell carcinoma stem-like cells.
Moon JH; Lee SH; Koo BS; Kim JM; Huang S; Cho JH; Eun YG; Shin HA; Lim YC
Oral Oncol; 2020 Dec; 111():104948. PubMed ID: 32771963
[TBL] [Abstract][Full Text] [Related]
15. Over-expression of BAG-1 in head and neck squamous cell carcinomas (HNSCC) is associated with cisplatin-resistance.
Liu S; Ren B; Gao H; Liao S; Zhai YX; Li S; Su XJ; Jin P; Stroncek D; Xu Z; Zeng Q; Li Y
J Transl Med; 2017 Sep; 15(1):189. PubMed ID: 28877725
[TBL] [Abstract][Full Text] [Related]
16. Combined treatment with cisplatin and the tankyrase inhibitor XAV-939 increases cytotoxicity, abrogates cancer-stem-like cell phenotype and increases chemosensitivity of head-and-neck squamous-cell carcinoma cells.
Roy S; Roy S; Kar M; Chakraborty A; Kumar A; Delogu F; Asthana S; Hande MP; Banerjee B
Mutat Res Genet Toxicol Environ Mutagen; 2019 Oct; 846():503084. PubMed ID: 31585633
[TBL] [Abstract][Full Text] [Related]
17. Cisplatin exposure causes c-Myc-dependent resistance to CDK4/6 inhibition in HPV-negative head and neck squamous cell carcinoma.
Robinson AM; Rathore R; Redlich NJ; Adkins DR; VanArsdale T; Van Tine BA; Michel LS
Cell Death Dis; 2019 Nov; 10(11):867. PubMed ID: 31727874
[TBL] [Abstract][Full Text] [Related]
18. HPV and CSC in HNSCC cisplatin resistance.
Modur V; Thomas-Robbins K; Rao K
Front Biosci (Elite Ed); 2015 Jan; 7(1):58-66. PubMed ID: 25553363
[TBL] [Abstract][Full Text] [Related]
19. Novel mechanism of cisplatin resistance in head and neck squamous cell carcinoma involving extracellular vesicles and a copper transporter system.
Ogawa T; Ono K; Ryumon S; Kawai H; Nakamura T; Umemori K; Yoshida K; Kanemoto H; Obata K; Yoshioka N; Okui T; Okamoto K; Nagatsuka H; Ibaragi S
Head Neck; 2024 Mar; 46(3):636-650. PubMed ID: 38164660
[TBL] [Abstract][Full Text] [Related]
20. Cultivation of Head and Neck Squamous Cell Carcinoma Cells with Wound Fluid Leads to Cisplatin Resistance via Epithelial-Mesenchymal Transition Induction.
Meyer TJ; Stöth M; Moratin H; Ickrath P; Herrmann M; Kleinsasser N; Hagen R; Hackenberg S; Scherzad A
Int J Mol Sci; 2021 Apr; 22(9):. PubMed ID: 33922946
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]